Research
Novel nanomedicine developed for rheumatoid arthritis

A team of researchers from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has developed a novel cinnamaldehyde-based prodrug nanomedicine for rheumatoid arthritis by utilising cinnamaldehyde, a common food additive, as an anti-inflammatory agent.
The novel prodrug forms nanoparticles that deliver the therapeutic agents precisely to the inflamed sites, offering a solution for the treatment of inflammatory diseases like rheumatoid arthritis.
Inflammation is a biological self-response mechanism to protect the human body from injury and infection caused by harmful stimuli. Generally, an inflammatory response can assist the body in self-defence and repair. However, dysregulated inflammatory responses may result in the development of various inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.
The primary cause of these conditions involves the loosening of endothelial junctions, which allows inflammatory cell recruitment and infiltration into inflamed tissue.
This lead to activated inflammatory cells promoting the overproduction of various pro-inflammatory cytokines, which are responsible for the initiation and progression of inflammatory lesions. Therefore, the suppression of excessive pro-inflammatory cytokines is essential for the prevention, alleviation, and treatment of various inflammatory diseases.
As the disease progresses, the deterioration of the joints significantly impairs their ability to function, causing irreversible damage to their health and quality of life.
The current treatment strategies for inflammatory diseases involve primarily the use of anti-inflammatory medications, including non-steroidal anti-inflammatory drugs, steroids, and biological agents.
In severe cases, surgical intervention may be required as an adjunct therapy. Despite remarkable advances in anti-inflammation and relief of clinical symptoms, the current treatment approach has been restricted by insufficient therapeutic efficacy and unfavourable systemic adverse effects due to the lack of targeting ability, poor stability, and low water solubility.
Research findings and significance
Through chemical modification, the research team transformed cinnamaldehyde into a reactive oxygen species-responsive polymeric prodrug that can self-assemble into nanoparticles. In experiments on two mouse models with RA and ulcerative colitis, the researchers found that these nanoparticles effectively accumulated at inflamed sites of the mice through intravenous injection.
The accumulated nanoparticles released cinnamaldehyde in response to high concentrations of reactive oxygen species at the inflamed sites, which alleviated the progression of inflammation by inhibiting the overproduction of pro-inflammatory cytokines.
The results from the mouse model studies demonstrated that the cinnamaldehyde prodrug nanomedicine can be precisely delivered to the inflamed sites, unleashing their therapeutic effects without causing damage to other normal tissues.
Professor Wang Weiping, Associate Professor of Dr Li Dak-Sum Research Centre and Department of Pharmacology and Pharmacy, HKUMed, and the research member of the State Key Laboratory of Pharmaceutical Biotechnology, HKU, who led the research project, pointed out that this technology has three major benefits.
“First, the team transformed cinnamaldehyde into a prodrug form through chemical modification, which can effectively improve the solubility and stability of the drug, making it easier for the body to absorb and maintain its activity,” Professor Wang Weiping explained.
“Second, administering the drug in a nanoparticle form increases the accumulation of the drug at the site of inflammation, avoiding rapid metabolism of the drug and enhancing its therapeutic efficacy. Third, reactive oxygen species at the inflamed site can activate the drug to exert its effects in the affected area. The cinnamaldehyde prodrug has a better therapeutic efficacy than traditional drugs, providing a groundbreaking approach for targeted drug delivery in the treatment of inflammatory diseases.”
Professor Wang and his team are currently working on developing an oral dosage form of cinnamaldehyde prodrugs, to help patients easily comply with their doctor’s instructions for medication and promote future clinical translation.
News
Two teas or coffees a day could lower dementia risk, experts say
News
Genetic influence on lifespan underestimated by half
News
Aerska raises US$39m for brain RNA medicines

Biotechnology company Aerska has raised US$39m in Series A funding to develop brain-delivered RNA medicines.
The company is developing treatments for neurological diseases, including genetically driven forms of Alzheimer’s disease.
This takes Aerska’s total funding to US$60m, months after its seed funding announcement in October 2025.
The company’s platform uses what it calls “brain shuttle” technology to help RNA therapeutics cross the blood-brain barrier, a protective membrane that normally prevents many drugs reaching the brain. RNA interference is a biological process where RNA molecules can silence or reduce the activity of specific genes.
The approach is designed to allow intravenous or subcutaneous administration, with the aim of achieving uniform brain distribution.
The financing was led by EQT Dementia Fund and age1, with participation from Iaso Ventures, alongside existing investors.
Chief executive and co-founder Jack O’Meara said: “The ability to systemically administer RNAi therapies to the brain unlocks a powerful new approach to treating neurodegeneration.
“Partnering with EQT Dementia Fund further strengthens our path to the clinic as we work to translate this capability into meaningful therapies for the treatment of genetically-driven forms of Alzheimer’s disease and other devastating brain disorders.”
As part of the financing, Arno de Wilde, managing director at EQT, Philip Scheltens, partner and head of the Dementia Fund at EQT, and Alex Colville, general partner at age1, will join Aerska’s board of directors.
Scheltens said: “For families facing diseases like Alzheimer’s, Aerska’s approach offers hope for preserving cognitive function and quality of life.
“The team’s strategy of upstream intervention, combined with a focus on the genetic forms of neurological disease, positions them to transform outcomes for populations who have been underserved by current therapeutic approaches.
“We really look forward to working with this talented team to advance this groundbreaking platform.”
News4 weeks agoInterview: GlycanAge launch first hospital-based tests
News3 weeks agoShingles vaccine may slow biological ageing in older adults
News4 weeks agoOlder male athletes may face increased risk of serious heart problems during exercise
News3 weeks agoThousands of men in England to be offered life-extending prostate cancer drug
News3 weeks agoNanoparticles target disease proteins in dementia
News3 weeks agoL-Nutra raises US$36.5m in series D funding
Insights4 weeks agoBlood sugar spike after meals may increase Alzheimer’s risk
Insights4 weeks agoStudy reveals why memory declines with age





















